



# Product Recall

in 26 jurisdictions worldwide

Contributing editor: Mark Tyler

# 2011



Published by  
*Getting The Deal Through*  
in association with:

Ajumogobia & Okeke

Anderson Mōri & Tomotsune

Bahas, Gramatidis & Partners

Brandi Advogados

Clayton Utz

Drzewiecki, Tomaszek & Partners

EBA – Endrös Baum Associés

Elegis – Huybrechts, Engels, Craen & Vennoten

Gorissen Federspiel

Karasek Wietrzyk Rechtsanwälte GmbH

Kim & Chang

Law Firm Šarka, Sabaliauskas, Jankauskas

McCague Borlack LLP

MMLC Group

Monereo Meyer Marine-Lo

Noerr

Shook, Hardy & Bacon LLP

S Horowitz & Co

Sprovieri – Dell'Oca Abogados

## Product Recall 2011

**Contributing editor:** Mark Tyler  
Shook, Hardy & Bacon  
International LLP

**Business development manager**  
Joseph Samuel

### Marketing managers

Alan Lee  
George Ingledew  
Robyn Hetherington  
Dan White  
Ellie Notley  
Sarah Walsh

### Marketing assistant

Alice Hazard

### Subscriptions manager

Nadine Radcliffe  
Subscriptions@  
GettingTheDealThrough.com

### Assistant editor

Adam Myers

### Editorial assistant

Nina Nowak

### Senior production editor

Jonathan Cowie

### Chief subeditor

Jonathan Allen

### Senior subeditor

Kathryn Smuland

### Subeditors

Chloe Harries  
Davet Hyland

### Editor-in-chief

Callum Campbell

### Publisher

Richard Davey

### Product Recall 2011

Published by  
Law Business Research Ltd  
87 Lancaster Road  
London, W11 1QQ, UK  
Tel: +44 20 7908 1188  
Fax: +44 20 7229 6910  
© Law Business Research Ltd  
2010

No photocopying: copyright  
licences do not apply.

ISSN 2042-2040

The information provided in this publication is general and may not apply in a specific situation. Legal advice should always be sought before taking any legal action based on the information provided. This information is not intended to create, nor does receipt of it constitute, a lawyer-client relationship. The publishers and authors accept no responsibility for any acts or omissions contained herein. Although the information provided is accurate as of December 2010, be advised that this is a developing area.

Printed and distributed by  
Encompass Print Solutions  
Tel: 0844 2480 112

**Law**

**Business**

**Research**

<b>Introduction</b> Mark Tyler <i>Shook, Hardy &amp; Bacon International LLP</i>	<b>3</b>
<b>Argentina</b> Luis Eduardo Sprovieri and Gastón Dell'Oca <i>Sprovieri – Dell'Oca Abogados</i>	<b>5</b>
<b>Australia</b> Colin Loveday and Richard Abraham <i>Clayton Utz</i>	<b>8</b>
<b>Austria</b> Thomas Frad <i>Karasek Wietrzyk Rechtsanwälte GmbH</i>	<b>14</b>
<b>Belgium</b> Annemie Coox, Katrien De Boeck and Diana Islamaj <i>Elegis – Huybrechts, Engels, Craen &amp; Vennoten</i>	<b>20</b>
<b>Brazil</b> Clarissa Borsoi, Joana Pacheco e Silva Figueira de Mello and Patrícia Saggiomo Martins Ferreira <i>Brandi Advogados</i>	<b>25</b>
<b>Canada</b> Mark Mason and Jason Rabin <i>McCague Borlack LLP</i>	<b>30</b>
<b>China</b> Ellen Wang and Yu Du <i>MMLC Group</i>	<b>36</b>
<b>Czech Republic</b> Philip Smitka <i>Noerr Prague (Noerr v.o.s.)</i>	<b>43</b>
<b>Denmark</b> Søren Stæhr and Christian Madsen <i>Gorrissen Federspiel</i>	<b>49</b>
<b>France</b> Florian Endrös and Muriel Mazaud <i>EBA – Endrös Baum Associés</i>	<b>54</b>
<b>Germany</b> Thomas Klindt and Michael Molitoris <i>Noerr LLP</i>	<b>59</b>
<b>Greece</b> Dimitris Emvalomenos and Panos Koromantzou <i>Bahas, Gramatidis &amp; Partners</i>	<b>65</b>
<b>Hungary</b> Eszter Sieber-Fazakas <i>Noerr Budapest (Noerr &amp; Partners Law Office)</i>	<b>71</b>
<b>Israel</b> Avi Ordo and Moran Katz <i>S Horowitz &amp; Co</i>	<b>77</b>
<b>Japan</b> Naoki Iguchi and Makoto Terazaki <i>Anderson Mōri &amp; Tomotsune</i>	<b>84</b>
<b>Korea</b> Jay (Young-June) Yang, Hyo Yeon Yoon and Brian C Oh <i>Kim &amp; Chang</i>	<b>88</b>
<b>Lithuania</b> Adomas Kunčius <i>Law Firm Šarka, Sabaliauskas, Jankauskas</i>	<b>93</b>
<b>Nigeria</b> Babatunde A Sodipo and Martins E Okonmah <i>Ajumogobia &amp; Okeke</i>	<b>97</b>
<b>Poland</b> Olga Szejnert-Roszak and Andrzej Tomaszek <i>Drzewiecki, Tomaszek &amp; Partners</i>	<b>101</b>
<b>Romania</b> Roxana Fercală, Diana Rizea and Gabriel Popa <i>Noerr Bucharest (SPRL Menzer &amp; Bachmann – Noerr)</i>	<b>106</b>
<b>Russia</b> Ekaterina Kalinina and Thomas Mundry <i>Noerr Moscow (Noerr OOO)</i>	<b>110</b>
<b>Slovakia</b> Pavol Rak and Zuzana Meinecke Fábry <i>Noerr Bratislava (Noerr s.r.o)</i>	<b>114</b>
<b>Spain</b> Sönke Lund and Ramon Romeu <i>Monereo Meyer MarineHo</i>	<b>119</b>
<b>Ukraine</b> Angelina Chachuna and Oleg Dorofeev <i>Noerr Kiev (Noerr TOV)</i>	<b>125</b>
<b>United Kingdom</b> Mark Tyler and Alison Newstead <i>Shook, Hardy &amp; Bacon International LLP</i>	<b>130</b>
<b>United States</b> Gregory L Fowler, Harley V Ratliff and Devin K Ross <i>Shook, Hardy &amp; Bacon LLP</i>	<b>136</b>

# United States

Gregory L Fowler, Harley V Ratliff and Devin K Ross

Shook, Hardy & Bacon LLP

---

## General product obligations

- 1 What are the basic laws governing the safety requirements that products must meet?

In the United States, product safety is regulated largely by various federal agencies. Each federal agency regulates a specific category of products, with occasional overlapping authority among agencies with respect to a particular product.

Given the breadth and diversity of products regulated by the federal government, this chapter focuses on the following three agencies: the Consumer Product Safety Commission (CPSC), the Food and Drug Administration (FDA), and the National Highway Traffic Safety Administration (NHTSA). These three agencies, and the laws they administer, regulate tens of thousands of different types of products, from prescription drugs and medical devices, to automobiles and to more than 15,000 types of consumer goods. The products regulated by these agencies are often involved in the most well-publicised safety recalls and are at the centre of much of the product liability litigation in the United States. The three primary product safety laws administered by these agencies are the Consumer Product Safety Act (CPSA), title 15 of the United States Code (USC) sections 2051 to 2089, the Food, Drug and Cosmetic Act (FDCA), 21 USC section 301, etc, and the Motor Vehicle Safety Act (MVSA), 49 USC section 30101, etc.

The CPSA applies to a broad range of consumer products defined generally as any product distributed for sale to a consumer for personal use in or around a home, school, or in recreation. In addition to the CPSA, the Consumer Product Safety Commission also administers four other product safety statutes: the Federal Hazardous Substances Act (FHSA), 15 USC sections 1261-78, the Flammable Fabrics Act (FFA), 15 USC sections 1191-1204, the Poison Prevention Packaging Act (PPPA), 15 USC sections 1471-77, and the Refrigerator Safety Act (RSA), 15 USC sections 1211-14. The FDCA regulates foods, drugs and devices intended for human or animal use, as well as any cosmetic or biologics intended for human use. While most foods (and food additives) are covered under the FDA's jurisdiction through the FDCA, certain foods, such as meat, poultry, and egg products, are regulated separately under the United States Department of Agriculture Food Safety and Inspection Service. For reference, the laws governing these specific food products include the Federal Meat Inspection Act (FMIA) 21 USC section 601, etc, and the Poultry Products Inspection Act (PPIA) 21 USC section 451 etc. Finally, the MVSA regulates motor vehicles and items of motor vehicle equipment. Through the MVSA, the National Highway Traffic Safety Administration establishes various federal motor vehicle safety standards.

- 2 What requirements exist for the traceability of products to facilitate recalls?

As a practical matter, the ability for a firm to trace its product at the various levels in the distribution chain is essential to effectively implement a recall. That said, there are few, if any, specific regulations

or requirements regarding the traceability of a product with regard to a recall. Depending on the agency, however, there may be more generally applicable traceability requirements to which the firm must comply. The FDA, as part of its quality system regulation scheme, requires that a manufacturer 'establish and maintain procedures for identifying the product during all stages of receipt, production, distribution, and installation to prevent mix-ups' (21 Code of Federal Regulations (CFR) section 820.65). Additionally, the manufacturer of a device intended for surgical implantation into the body must maintain procedures to identify finished devices and components, if such device or component is found to cause significant injury (21 CFR section 820.65). Recently, the CPSA was amended to add tracking label requirements for manufacturers of children's products in order to 'facilitate ascertaining the specific source of the [children's] product' (15 USC section 2063 (as amended by section 103 of the Consumer Product Safety Improvement Act of 2008 (CPSIA))).

- 3 What penalties may be imposed for non-compliance with these laws?

Both the CPSA and FDCA provide for civil and criminal penalties. Criminal penalties are typically imposed only after repeated, intentional, and fraudulent violations of the statutes. Civil penalties under both statutes may include a fine, administrative action, or both. Two significant administrative penalties include seizure and injunction. Under the CPSC and FDCA, a violative product, which has been distributed in interstate commerce, may be seized by the agency, an injunction entered preventing sale of the product, or both (21 USC section 334).

In addition to administrative penalties, both statutes provide for fines and incarceration for violating a statutory or regulatory provision. The penalties' provisions of the CPSA were recently amended by the CPSIA. Under the CPSIA, the maximum civil penalty per violation increased from US\$5,000 to US\$100,000. The maximum civil penalty for a related series of violations increased from US\$1.25 million to US\$15 million. Criminal penalties increased from one to five years maximum imprisonment for a knowing and willing violation. A criminal violation of a CPSC-enforced regulation may also result in forfeiture of the assets associated with the violation. Under the FDCA the specific penalty available will be determined based on the alleged violation and violative product. Penalties can range from US\$1,000 to US\$1 million; and one to 10 years' imprisonment. Penalties under the FDCA are more severe if the violation was undertaken knowingly and if death resulted based on a violation (21 USC section 333).

---

## Reporting requirements for defective products

- 4 What requirements are there to notify government authorities (or other bodies) of defects discovered in products, or known incidents of personal injury or property damage?

A manufacturer of regulated products must notify the applicable regulating authority regarding substantial safety deficiencies in its products. Although each agency maintains different thresholds and

reporting requirements, all agencies rely, in large part, on the self-reporting of firms in determining product safety issues.

Under the CPSA, for example, there are two basic reporting requirements. First, a manufacturer, importer, distributor, or retailer of a consumer product is required to report under section 15(b) when a product does not comply with a safety rule issued under the CPSA, contains a defect that could create a substantial product hazard to consumers, or creates an unreasonable risk of serious injury or death. Second, under section 37, a manufacturer of consumer products must report information about lawsuits or settlements if: a particular model of the product is the subject of at least three civil actions filed in a federal or state court within a 24-month period; each suit alleges death or grievous bodily injury; and at least three of the suits result in final settlement or judgment in favour of the plaintiff.

The FDA also requires regulated companies to notify the agency immediately once the company becomes aware that the company's product is violative of a statute or regulation enforced by the FDA. Food manufacturers, processors, packagers and holders are required to notify the FDA as soon as they become aware that there is a reasonable probability that an article of food is 'reportable'. An article of food is considered 'reportable' if there 'is a reasonable probability that the use of, or exposure to, such article of food will cause serious adverse health consequences or death to humans or animals' (21 USC section 350f(a)). The FDA also requires that companies report serious and unexpected adverse events associated with new drugs, approved drugs, non-prescription drugs and dietary supplements as soon as possible, 'but no later than 15 calendar days of initial receipt of the information [...] (21 CFR section 314.80(c) and 21 CFR section 305(c)).

Finally, under 49 USC section 30118, a manufacturer of a motor vehicle or an item of 'original equipment' (an item of motor vehicle equipment which was installed in or on a motor vehicle at the time of its delivery to the first purchaser) must report to the NHTSA within five working days from determining that a safety defect or non-compliance exists in the manufacturer's product.

**5** What criteria apply for determining when a matter requires notification and what are the time limits for notification?

A firm's reporting obligations typically begin once the firm becomes aware that its product poses a risk to the safety of a user or consumer, or is otherwise in violation of a statutory or regulatory requirement, such as a safety standard. The specific reporting criteria and requirements, including when the information must be reported, depend on the product at issue and corresponding agency's regulations.

For example, under section 15 of the CPSA, a firm must report within 24 hours of obtaining information that reasonably supports the conclusion that a product does not comply with a safety rule issued under the CPSA, contains a defect that could create a substantial product hazard to consumers, or presents an unreasonable risk of injury or death. The obligation to report commences upon receipt of the reportable information, although the CPSC does allow an extra 10 days for the company to conduct 'expeditious investigation' in order to evaluate whether the information is reportable.

Likewise, the FDA's reporting obligation for drugs, non-prescription drugs for human use, and dietary supplements arises upon notice of a 'serious adverse event'. Title 21 USC section 379aa defines a serious adverse event as an adverse event that results in life-threatening injury, death, hospitalisation, disability, birth defect, or requires medical or surgical intervention to prevent death, disability or birth defects. A report of a serious adverse event must be made to the FDA no later than 15 business days after the report is received by the company. Facilities responsible for the production or packaging of food are required to notify the FDA 'as soon as practicable, but in no case later than 24 hours after a responsible party determines that an article of food is reportable [...]' (21 USC section 350f(d)).

The specific regulating agency for particular classes of products is discussed in question 6.

**6** To which authority should notification be sent? Does this vary according to the product in question?

The particular authority to which notification should be sent – as well as the kind of information to be reported as part of the notification – depends on the kind of product at issue. A list of general product types and the corresponding regulating federal agency is listed below. Additional information about the specific types of products regulated by each agency can be located at the agency's website.

- Aircraft: Federal Aviation Administration: [www.faa.gov](http://www.faa.gov).
- Alcohol: Alcohol and Tobacco Tax and Trade Bureau: [www.ttb.gov](http://www.ttb.gov).
- Boats: US Coast Guard: [www.uscgboating.org](http://www.uscgboating.org).
- Consumer products: Consumer Products Safety Commission: [www.cpsc.gov/businfo/reg1.html](http://www.cpsc.gov/businfo/reg1.html).
- Cosmetics: Food and Drug Administration: [www.fda.gov](http://www.fda.gov).
- Drugs and medical devices: Food and Drug Administration: [www.fda.gov](http://www.fda.gov).
- Industrial, commercial or farm products: Occupational Safety & Health Administration: [www.osha.gov](http://www.osha.gov).
- Firearms and ammunition: Bureau of Alcohol, Tobacco, and Firearms: [www.atf.gov](http://www.atf.gov).
- Food (meat, poultry, and processed eggs): Department of Agriculture: [www.fsis.usda.gov](http://www.fsis.usda.gov).
- Food (except meat, poultry, and processed eggs): Food and Drug Administration: [www.fda.gov](http://www.fda.gov).
- Motor vehicles (including tires, car seats, and parts): National Highway Traffic Safety Administration: [www.safercar.gov](http://www.safercar.gov).
- Pesticides, rodenticides, and fungicides: Environmental Protection Agency: [www.epa.gov](http://www.epa.gov).
- Tobacco and tobacco products: Alcohol and Tobacco Tax and Trade Bureau: [www.ttb.gov](http://www.ttb.gov).

**7** What product information and other data should be provided in the notification to the competent authority?

Each regulatory agency will have its own requirements for what specific product information must be reported and what forms need to be completed as part of the notification process.

For example, the CPSC provides an on-line 'initial report' that companies can use to report potentially defective or hazardous products pursuant to section 15 of the CPSA. The initial report can be completed at [www.cpsc.gov/cgibin/sec15.aspx](http://www.cpsc.gov/cgibin/sec15.aspx). The reporting should be done by a person with knowledge of the product and the reporting requirements of section 15. The initial report should include the following information: description of the product; name and address of the company and whether it is a manufacturer, distributor, importer, or retailer; nature and extent of the possible product defect or unreasonable risk of serious injury or death; nature and extent of injury or possible injury associated with the product; name, address, and telephone number of the person informing the Commission; and, if necessary, a timetable for providing information not immediately available. Following the filing of an initial report, a 'full report', is required to be submitted by the reporting firm. The full report requires more detailed product information than the initial report, including, but not limited to, such information as technical drawings, test results, and schematics; a chronological account of facts and events leading up to the report; and model numbers, serial numbers, and data codes of the affected products. The complete list of information required by the full report is set forth in section 1115.13(d)(1)-(15).

The FDA requires that serious and unexpected adverse events be reported using FDA Form 3500A, which is available at [www.fda.gov/medwatch/safety/fda-3500a\\_fillable.pdf](http://www.fda.gov/medwatch/safety/fda-3500a_fillable.pdf). This form provides

the required information necessary for the mandatory submission of serious adverse events. Some of the information required includes: name of the suspected product; description of the adverse event; relevant history associated with the specific adverse event; and other information regarding manufacturers, importers and users of the product. Reports regarding serious adverse health consequences or death from articles of food should include information concerning date and nature of food adulteration; product information; contact information at the reporting facility; and the contact information for parties ‘directly linked in the supply chain’ for the reportable food (21 USC section 350f(e)).

Finally, the NHTSA requires a manufacturer to complete a ‘defect and noncompliance information report’ (also known as a ‘573 Report’) once it determines there is a defect in its product (49 CFR section 573.6). Information that must be provided in this document includes, at a minimum: the manufacturer’s name; identification of the product containing the defect with a description of the manufacturer’s determination of the population subject to the defect; and a description of the defect or non-compliance, including a brief summary and a detailed description of the defect (49 CFR section 573.6(c)). The regulations recognise additional information that a manufacturer should submit as it becomes available.

**8** What obligations are there to provide authorities with updated information about risks, or respond to their enquiries?

In order to ensure the adequate completion of recalls and other safety notifications, most regulating agencies require firms to submit various reporting documents regarding the status of the recall and the ongoing risks presented by the violative product. The ongoing reporting requirements and obligations will vary depending on the agency and product involved. The NHTSA, for example, requires that a recalling manufacturer submit quarterly recall reports under 49 CFR section 573.7. The specific information submitted in these reports includes, but is not limited to: date the notification campaign began and was completed; the number of vehicles or items involved in the campaign; the number of vehicles inspected; and the number of vehicles determined to be unreachable. These quarterly reports are due on or before the 30th day of each month following the end of each calendar quarter (ie, 30 April, 30 July, 30 October, and 30 January) (49 CFR section 537.7(d)).

**9** What are the penalties for failure to comply with reporting obligations?

The failure to comply with reporting obligations is typically considered a prohibited act and may subject the firm to civil penalties, criminal penalties, or both (see, for example 15 USC sections 2069-72). A firm that intentionally fails to comply with the statutory reporting obligations may be deemed to ‘knowingly’ commit a prohibited act and be subject to more severe penalties under the appropriate regulatory framework. A motor vehicle manufacturer that fails to comply with the reporting requirements imposed by the MVSA can be fined up to US\$15 million (49 USC section 30165(a)(1)). In addition to civil and criminal penalties, a drug manufacturer that fails to comply with its reporting requirements also risks having FDA approval of its drug withdrawn (21 CFR section 314.150 (b)).

**10** Is commercially sensitive information that has been notified to the authorities protected from public disclosure?

In the United States, the Freedom of Information Act (FOIA) allows for members of the public to access information controlled by the United States government. A firm may seek to protect information submitted to a regulatory agency from the reach of the FOIA. For example, firms reporting under both the CPSA and FDCA are, in certain situations, provided with protection from FOIA requests.

The CPSA prevents the public disclosure of proprietary and confidential information. However, information included in a section 15(b) report can otherwise be made available to the public, through an FOIA request, after remedial action is requested, or if the submitting firm consents. The Commission must notify the company prior to the release of any information to the public and allow the submitting company an opportunity to object. The CPSIA recently reduced the time within which a company may object to the release of information from 30 day to 15 days. Additionally, the CPSIA allowed for the CPSC to further shorten this period if it determines that ‘the public health and safety requires public disclosure within a lesser period of notice’ (15 USC section 2055).

A firm reporting under the FDCA is protected from the disclosure of trade secrets and confidential commercial information (21 CFR section 20.61). If the FDA disagrees with a firm’s classification of the information as confidential, the FDA may determine that disclosure is appropriate. In such cases, the FDA will provide the submitting entity notice of the request and the opportunity to object to disclosure. The firm will have five working days from receiving the notice to object to the disclosure under these regulations (21 CFR section 20.61(e)(1)-(2)).

**11** May information notified to the authorities be used in a criminal prosecution?

Generally no distinction is made between disclosure of information based on civil or criminal proceedings. The CPSC, however, expressly provides that information submitted pursuant to section 37 will be immune from disclosure except for an action brought against the manufacturer for failure to provide information required by section 37 (15 USC section 2055(e)(2)). Therefore such information could be used against the manufacturer in a suit brought against it by the Commission (15 USC section 2070).

**Product recall requirements**

**12** What criteria apply for determining when a matter requires a product recall or other corrective actions?

Once a firm becomes aware that its product is in violation of a statutory or regulatory provision of the agency and presents a threat to safety or the product creates a substantial risk of injury to the public, even though it is not in violation of any applicable rule, the implementation of a corrective action should be considered (see, for example, 15 USC section 2064). The decision to recall a product is an important one and can be made voluntarily, at the request of the regulating agency, or both. If, however, the regulatory agency requests the product be recalled as an alternative to other administrative action, a firm should consider undertaking such action so as to avoid incurring harsher administrative penalties.

**13** What are the legal requirements to publish warnings or other information to product users or to suppliers regarding product defects and associated hazards, or to recall defective products from the market?

The requirements regarding publication of warnings and other information about a defective or dangerous product vary. For some products, statutes mandate that the manufacturer make specific notifications to all owners, purchasers, and dealers of the product (see, for example 49 USC section 30118(b)). Most agencies provide guidance documents or product recall handbooks outlining suggested medium for publishing such information. See also the discussion in questions 7 and 14.



**14** Are there requirements or guidelines for the content of recall notices?

All agencies provide guidelines regarding the content of recall notices and communications concerning products under their jurisdiction. Most recall or safety communications include information such as: the name of the recalling firm; the firm's contact information; the name of the product being recalled; a general description of the danger posed by the product; and specific instructions on what should be done with respect to the recalled product. Additional information such as model numbers, colour photographs, or line drawings may be helpful or required depending on the particular product and media used for the notification (15 USC section 2064(i)). The MVSA specifically mandates seven elements that must be included in notices for motor vehicle recalls (49 USC section 30119).

**15** What media must be used to publish or otherwise communicate warnings or recalls to users or suppliers?

No specific requirements exist as to the exact media that must be used in communicating warning or recall information to ultimate users or suppliers. Each regulatory agency provides its own guidelines and review of sent and proposed communications. However, a press release (submitted jointly or independently by the firm) is usually considered an initial step in communicating information to a wide range of consumers. Depending on the product, the degree of the risk posed, and the specific distribution chain, other forms of media may also be appropriate or required, ranging from publication of notices in newspapers to direct contact with consumers via mailings, e-mail or telephone.

**16** Do laws, regulation or guidelines specify targets or a period after which a recall is deemed to be satisfactory?

In most product recalls, the number of products that must be retrieved and the time period for which the recall must be conducted is a subjective fact-specific determination made on a case-by-case basis by the appropriate regulatory agency.

For example, in a recall involving a CPSC-regulated product, the recalling firm may submit a final progress report and request that the file be closed once the firm has determined that its corrective action plan has been implemented to the best of its ability and as many of the recalled products as possible have been removed from the marketplace. The CPSC will then review the plan's progress and decide whether the file should be closed. If the CPSC determines the plan has not been effective, it may request that the firm implement broader corrective action measures.

Likewise, the FDA will terminate a recall when it 'determines that all reasonable efforts have been made to remove or correct the product in accordance with the recall strategy, and when it is reasonable to assume that the product subject to the recall has been removed and proper disposition or correction has been made commensurate with the degree of hazard of the recalled product'. A firm may request that the FDA make such a determination by submitting to the district office a statement in writing that the recall has achieved the articulated goals and including the most recent recall status report.

**17** Must a producer or other supplier repair or replace recalled products, or offer other compensation?

Although not always mandatory, nearly all product recalls in the United States include some form of replacement, repair, or other compensation mechanism. For example, the CPSC may not approve a firm's proposed corrective action plan without some form of consumer remedy. Similarly, the FDA has authority to order a manufacturer, importer, or any distributor of a device intended for human use, which the FDA determines presents 'an unreasonable risk of substan-

tial harm to the public health' to undertake the repair, replacement, or refund of the device or a combination of all three (21 USC section 360h(b)(1)(A)-(2) (2009)). Before issuing such an order, the FDA must provide the firm with an opportunity for an informal hearing at which time the firm may object to the classification of the FDA. Finally, it should be noted that providing a consumer remedy, even when not required by statute, may help achieve the appropriate level of consumer participation required by the administrative agency. By contrast, the MVSA specifically mandates that motor vehicle manufacturers remedy any defects without charge to the consumer (49 USC section 30120).

**18** What are the penalties for failure to undertake a recall or other corrective actions?

Most product recalls are conducted voluntarily by firms, which may obviate more burdensome administrative procedures provided by statute (eg, seizure, detention and injunction). Therefore, a firm that fails to voluntarily initiate a product recall, or rejects to undertake a requested recall, may run the risk of being subjected to these harsher penalties.

**Authorities' powers****19** What powers do the authorities have to compel manufacturers or others in the supply chain to undertake a recall or to take other corrective actions?

The authority to compel recalls or take other corrective action varies by product and agency. In most cases manufacturers voluntarily initiate recalls and the agency merely provides oversight and assistance with developing a recall plan. However, in some instances the regulating agency can override a manufacturer's decision regarding the need for a recall, and take corrective action of its own.

For example, the secretary of the NHTSA can issue recall orders to motor vehicle manufacturers requiring them to give notice to all owners, purchasers, and dealers as well as remedy the defect (49 USC section 30118(b)). Manufacturers are entitled to a hearing, and have the right to challenge the recall order in a United States district court (49 USC section 30121). Additionally, the FDA has the power to initiate recalls in four limited contexts: medical devices intended for human use (section 518(e)), biological products intended for human use (42 USC section 262), human tissue intended for transplantation (21 CFR section 1271.440), and misbranded or adulterated infant formula and interstate milk shipments (21 USC section 350a(e)-(g)). Furthermore, even where the FDA cannot otherwise compel a manufacturer to recall its drug, it may suspend or withdraw approval of the drug upon finding the drug presents an imminent hazard to public health (21 USC section 355(e)).

For most consumer products the agency seeking to compel a recall must resort to filing an action in federal court for either an injunction or seizure of the defective products (16 CFR section 1115.21). The CPSA also authorises such actions to be brought by the attorneys general for states in which a defective product is sold (15 USC 2073(b)).

**20** Can the government authorities publish warnings or other information to users or suppliers?

In most situations, the administrative agency works with the recalling firm in drafting and approving all product safety or recall communications. The agency will then post recall notices or other pertinent safety information on the agency's website or specific recall websites such as [www.recalls.gov](http://www.recalls.gov). For example, the FDA publishes a weekly 'enforcement report' regarding recently initiated recalls. The Enforcement Report communicates the particular recall classification, whether the recall was voluntary or requested by the FDA, and

**Update and trends**

The Chinese export recalls that dominated the US media in recent years have taken a backseat to a recent spate of automobile recalls. In the last year, nearly every major car manufacturer including Ford, Toyota, Honda and Nissan has announced major product recalls nationwide. The breadth of these recalls and the media attention they have received has led to consequences in both the litigation and regulatory worlds.

The Toyota recalls, for example, received extensive media coverage during the first part of 2010 – coverage that has since been criticised by many of the industry’s leading publications. As with all well-publicised product recalls, litigation against Toyota followed shortly thereafter, and individual and class-action lawsuits have been filed in state and federal courts across the country. On 9 April 2010, the Judicial Panel on Multidistrict Litigation consolidated many of the federal actions into the US District Court for the Central District California for all pre-trial proceedings. The plaintiffs’ lead counsel for that litigation was recently selected and discovery is now under way.

Congress has responded to the recent automobile recalls with new legislation aimed at raising motor vehicle safety standards as well as deterring violations of the MVSA. Both the United States Senate and the House of Representatives have begun preparing and voting on drafts of the proposed Motor Vehicle Safety Act of 2010. The

Senate bill, introduced by Senator Jay Rockefeller, contains additional safety provisions including mandatory break override systems, keyless ignition standards, and mandatory vehicle event data recorders (similar to the ‘black boxes’ now found on aeroplanes). The bill would also raise the per-vehicle civil penalty from US\$5,000 to US\$25,000 and would remove all previous statutory caps on civil penalties.

Looking ahead, the next hot topic in product recall litigation may be a rebirth in litigation involving ‘360k medical devices’. In one of the most talked about Supreme Court cases in recent years, the Court in *Riegel v Medtronic, Inc*, 129 S Ct 999 (2008), held that under 21 USC section 360k(a), state-law tort claims against medical device manufacturers are pre-empted so long as the device at issue was approved by the FDA. The decision gave manufacturers a strong pre-emption defence in any product liability action. Since that decision, groups in both Houses of Congress have proposed amendments to the Medical Device Amendments of 1976 that would overrule *Riegel*. Representative Frank Pallone, Jr, for example, has proposed HR Bill 6381 entitled the ‘Medical Device Safety Act of 2008’. With the current makeup of Congress, the passage of these amendments has become more likely and may usher in a new era of 360k medical device litigation.

the action being taken by the recalling firm (21 CFR section 7.50). If an agency feels the recalling firm is lacking in its recall efforts, the agency may choose to publish information to consumers directly that is critical of the recalling firm and generally unfavourable.

- 21 Can the government authority organise a product recall where a producer or other responsible party has not already done so?

Generally, product recalls are undertaken voluntarily by a firm, with the respective agency lacking authority to initiate a recall. Firms often chose to voluntarily conduct a recall that may obviate other possible administrative actions available under the respective agency’s statutes, such as seizure or injunction. As discussed in question 19, there are certain products for which Congress has provided explicit recall authority. As a practical matter, even where an administrative agency lacks the specific authority to initiate a recall, a firm requested to do so should consider complying with this request in order to avoid the statutory alternatives.

- 22 Are any costs incurred by the government authority in relation to product safety issues or product recalls recoverable from the producer or other responsible party?

A firm will usually not be responsible for costs relating to the government’s actions regarding a safety issue or product recall. However, a

court could, upon conviction, order payment of the agency’s cost of investigation (28 USC section 1918(b)).

- 23 How may decisions of the authorities be challenged?

The decision by a firm to recall a product, in most cases, is voluntary and is undertaken with the assistance and input of the applicable regulatory agency. Many of the agency’s decisions during the recall process are negotiated between the agency and the recalling firm. However, in situations where the agency may seek to pursue statutory remedies such as seizure or detention, a regulated firm may desire to challenge the decision of the regulating authority. In such situations, the firm will typically have a limited opportunity to present evidence that the product in fact complies with (or does not violate) the applicable statutes, standards, or regulations. The regulatory authority will review the evidence and make a determination.

**Implications for product liability claims**

- 24 Is the publication of a safety warning or a product recall likely to be viewed by the civil courts as an admission of liability for defective products?

When determining tort liability, the publication of a safety warning or the initiation of a product recall is generally not considered a per se legal admission that the product at issue is defective. The CPSA, for

# Shook, Hardy & Bacon LLP

**Gregory L Fowler**

**gfowler@shb.com**

2555 Grand Blvd  
Kansas City, Missouri 64108  
United States

Tel: +1 816 474 6550  
Fax: +1 816 421 5547  
www.shb.com

example, expressly recognises that the use and definition of ‘defect’ are ‘not intended to apply to any other area of the law’ (16 CFR section 1115.4 (2009)). Likewise, the FDCA has a similar provision that states that information submitted in connection with the safety of a product shall not be construed to reflect a conclusion by the reporting firm ‘that the report or information constitutes an admission that the product involved malfunctioned, caused or contributed to an adverse experience, or otherwise caused or contributed to a death, serious injury, or serious illness’ (21 CFR section 379v).

It should also be noted that, in practice, lay jurors may find it difficult to grasp the concept that a product that was recalled or labelled defective by the governing regulatory authority should not, in turn, also be considered ‘defective’ or as a basis for liability under the applicable state law. To that end, companies do have the benefit of limited legal safeguards, such as pre-trial in limine motions (which can be used to attempt to exclude or limit evidence of the recall) and proposed jury instructions (which can be used to focus the jurors on the correct legal standards).

---

**25** Can communications, internal reports, investigations into defects or planned corrective actions be disclosed through court discovery processes to claimants in product liability actions?

Companies can expect that evidence such as internal reports or planned corrective actions will be disclosed to an adverse party during the pre-trial discovery process. There are, however, certain categories of potentially relevant evidence that may – depending on the situation – be protected from disclosure. These include: communications between client and counsel, attorney work product and documents created in anticipation of litigation. In such situations, the company will have to state the basis for its non-disclosure, which can then be challenged by the adverse party. It should be noted that information or documents disclosed, or testimony given during the pre-trial process will not necessarily be admissible at trial. For example, documents and other evidence of the company’s subsequent remedial measures may be considered ‘discoverable’ but not ultimately ‘admissible’ in court. Conversely, courts are likely to admit evidence that a product was recalled, but may impose certain limitations on the use of such evidence at trial.









**GETTING THE DEAL THROUGH®**

**Annual volumes published on:**

Air Transport	Merger Control
Anti-Corruption Regulation	Mergers & Acquisitions
Arbitration	Mining
Banking Regulation	Oil Regulation
Cartel Regulation	Patents
Climate Regulation	Pharmaceutical Antitrust
Construction	Private Antitrust Litigation
Copyright	Private Equity
Corporate Governance	Product Liability
Dispute Resolution	Product Recall
Dominance	Project Finance
e-Commerce	Public Procurement
Electricity Regulation	Real Estate
Environment	Restructuring & Insolvency
Franchise	Right of Publicity
Gas Regulation	Securities Finance
Insurance & Reinsurance	Shipping
Intellectual Property & Antitrust	Tax on Inbound Investment
Labour & Employment	Telecoms and Media
Licensing	Trademarks
Life Sciences	Vertical Agreements

**For more information or to  
purchase books, please visit:  
[www.gettingthedealthrough.com](http://www.gettingthedealthrough.com)**



Strategic research partners of  
the ABA International section



THE QUEEN'S AWARDS  
FOR ENTERPRISE  
2006



The Official Research Partner of  
the International Bar Association